Full Year 2024 Roche Holding AG Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Richard Vosser - JPMorgan - Analyst : Two questions from me, please. Firstly, one on the Vabysmo. I think we understand the temporary weakness in the quarter, but I wanted to ask about the launch of a prefilled syringe for high-dose Eylea and how you would see that affecting Vabysmo, Obviously, very key and you're doing really well with yours. But in Europe, they have a prefilled syringe for high-dose Eylea thinking about how that might affect you in '25. And then second question, just on giredestrant, maybe a little bit of a pushout on the persevERA data into Q4 and October on clinical trials. Just what do you see as the implications for that on your thoughts around the expectations for the results of the trial? Teresa Graham - Roche Holding AG - Member of the Corporate Executive Committee, Chief Executive Officer of Roche Pharmaceuticals I'll start with the last one. So I don't think that has really any implications on the results. Just sometimes these things take a little bit longer, and that's what we saw with giredestrant. The prefilled syringe, so I would just have to say, right now, we're really not seeing any impact in any part of the world from high-dose Eylea. And the prefilled syringe that we have in the market is materially different than the prefilled syringe that Eylea has. It has one hand administration, which when you think about it, if you're doing 1,000 shots or 100 shots a day, having that really ease of administration is super important. So I would say we definitely have a device preference going on our side. And quite frankly, I think just what is inside the syringe matters a lot. And Vabysmo is clearly continuing to distinguish itself from an efficacy and safety standpoint and with the add and convenience of the prefilled syringe. I would just continue to see it growing and continue to establish itself. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JANUARY 30, 2025 / 1:00PM, ROG.S - Full Year 2024 Roche Holding AG Earnings Call

Question: Richard Vosser - JPMorgan - Analyst : No. Bruno and Teresa, thank you very much. That's great. Thanks a lot.

Question: Justin Smith - Bernstein - Analyst : Number one, just on 007, and sorry if I missed this, but it seems as though since the CMD, it's been moved up to a non-risk-adjusted peak sales target of over CHF3 billion. Just wanted some color on that. And then just one on astegolamab, might be a little bit too early to ask. But one of your competitors sort of suggested that severe COPD, there's more sufferers, but efficacy of the biologics is probably likely to be lower than in severe asthma. So I just wondered if you have any thoughts on that? Teresa Graham - Roche Holding AG - Member of the Corporate Executive Committee, Chief Executive Officer of Roche Pharmaceuticals Yeah. So I'll answer the [SD] question first. I mean, that's why you run the clinical trial, right? So we'll see. We think there's a good scientific rationale for why this could work in COPD. We're covering a very broad patient population. It's an area of very high unmet need. So yeah, I would -- we'll know this year if it works. So stay tuned on that. But again, to your point, it's a little bit early to speculate. In terms of NXT007, if this if this molecule lives up to what we believe it can do, it will, for sure, becoming a new standard of care in hemophilia A and therefore, easily a multibillion-dollar indication. But it is -- the data that we've seen so far is exciting. It's early days, more to come.